GlaxoSmithKline PLC (GSK) stock prices updated...
 

GlaxoSmithKline PLC stock price

GlaxoSmithKline PLC latest news:


  • 12/05/2017 15:39:23

    BRIEF-ACCC Institutes Proceedings Against GSK, Novartis

    Australian Competition and Consumer Commission. * INSTITUTED PROCEEDINGS AGAINST GLAXOSMITHKLINE HEALTHCARE AUSTRALIA PTY LTD AND NOVARTIS CONSUMER HEALTH AUSTRALASIA. * PROCEEDINGS ALLEGING THEY MADE FALSE OR MISLEADING REPRESENTATIONS IN MARKETING OF VOLTAREN OSTEO GEL AND VOLTAREN EMULGEL PAIN RELIEF PRODUCTS.

  • 11/30/2017 00:49:29

    GSK starts big African study of injectable drug to prevent HIV

    ViiV Healthcare, GlaxoSmithKline Plc's HIV unit, said on Thursday it started an African study to evaluate long-acting injectable drug for the prevention of HIV infection in sexually active women. The cabotegravir study seeks to enrol 3,200 women aged 18 to 45 years from sub-Saharan African countries, ViiV Healthcare said in a statement.

  • 11/30/2017 00:41:47

    BRIEF-Glaxosmithkline says ViiV Healthcare starts Phase 3 HIV prevention study in women

    * ‍VIIV HEALTHCARE, CO OWNED BY GSK, WITH PFIZER INC. AND SHIONOGI LTD AS SHAREHOLDERS, TO START PHASE III STUDY FOR PREVENTION OF HIV INFECTION IN SEXUALLY ACTIVE WOMEN​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

  • 11/21/2017 12:25:13

    ViiV Healthcare says FDA has approved its two-drug HIV regimen, in first such instance

    ViiV Healthcare, which is majority-owned by GlaxoSmithKline and has Pfizer Inc. and Shionogi as shareholders, said on Tuesday that the Food and Drug Administration has approved its two-drug HIV regimen. The therapy, Juluca, is the first such HIV drug composed of just two drugs -- dolutegravir and rilpivirine, both of which have been previously approved -- while other HIV regimens are typically composed of at least three drugs. This advancement could make the regimen more tolerable for the patient, according to Dr. Debra Birnkrant, director of the Division of Antiviral Products in the FDA's Center for Drug Evaluation and Research. Juluca is approved for individuals with HIV-1 who have been stable on a regimen for at least half a year, have no history of treatment failure and no known resistance to Juluca's individual components, ViiV said. GlaxoSmithKline shares declined 0.8% in Tuesday trade; shares have dropped nearly 10% over the last three months, compared with a 7% rise in the S&P 500 and a nearly 8% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 11/16/2017 15:32:49

    BRIEF-‍GlaxoSmithKline reports 13.3 percent stake in Spero Therapeutics

    Spero Therapeutics Inc(SPRO). * ‍GlaxoSmithKline PLC reports a 13.3 percent stake in Spero Therapeutics Inc (SPRO) as of November 6 - SEC filing​ Source text: Further company coverage:

  • 11/08/2017 10:34:03

    BRIEF-Glaxosmithkline says ‍results of first study assessing levels of organ damage in patients with active SLE

    GLAXOSMITHKLINE PLC(GSK): * SAYS ‍RESULTS OF FIRST STUDY ASSESSING LEVELS OF ORGAN DAMAGE IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH BENLYSTA PLUS STANDARD OF CARE VERSUS SOC ALON​E. * ‍PATIENTS WITH SLE ARE AT RISK OF IRREVERSIBLE ORGAN DAMAGE, WHICH CAN ACCRUE OVER TIME AND IS ASSOCIATED WITH INCREASED RISK OF DEATH​. * ‍SAFETY PROFILE OBSERVED IN BLISS-76 LONG-TER...

  • 10/26/2017 01:39:40

    Pfizer sets date for auction of consumer healthcare unit: Reuters

    Pfizer Inc. will begin the auction process for its consumer healthcare unit in November, which it hopes will end in a $15 billion sale, Reuters reported late Wednesday, citing sources close to the matter. GlaxoSmithKline PLC. and Reckitt Benckiser are among those companies that have said they would consider bidding for the Pfizer unit. One of the sources told Reuters that initial discussions with Reckitt have already happened. Other possible bidders may include Procter & Gamble , Sanofi SA , Johnson & Johnson and Nestle [s: ch:nesn], sources said. The companies have been contacted for comment.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/25/2017 10:54:34

    GlaxoSmithKline stock plummets 6% after concerns about dividend risk

    GlaxoSmithKline PLC shares plummeted 6% in extremely heavy midday trade Wednesday on concerns that the company's interest in Pfizer Inc.'s over-the-counter business could put its dividend at risk. After being asked if she could give investors assurances that the potential deal would carry no dividend risk, Chief Executive Emma Walmsley did not exactly give those assurances. "We know the dividend matters to our investors. We intend and we do pay it now as a function of our free cash flow after investing in the necessary priorities to secure long-term growth for the company," Walmsley said, according to the FactSet transcript of the company's third-quarter earnings call, adding, "we confirmed our intentions to pay the dividend in 2017 of 80 pence and again in 2018 and then we will be returning to declaring the dividend quarterly and not giving a more specific outlook beyond that." When Walmsley was again pressed about the potential Pfizer deal, she said it was "too premature and hypothetical." "For us, even though we believe pricing (mostly in Respiratory) and competitive concerns (Respiratory and HIV) are largely factored into the stock at current levels, investors remain focused on the safety of the dividend," said Leerink Partners analyst Seamus Fernandez. GlaxoSmithKline shares have dropped 9.5% over the last three months, compared with a 2.9% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/25/2017 09:51:00

    GlaxoSmithKline on target thanks to HIV and lung drugs

    Pharmaceutical giant GlaxoSmithKline's third-quarter sales are helped by demand for new products.

  • 10/20/2017 16:50:08

    GlaxoSmithKline adult shingles vaccine wins U.S. approval

    The U.S. Food and Drug Administration approved GlaxoSmithKline's Shingrix shingles vaccine for use in adults aged 50 and over, a move widely expected after an advisory panel to the agency last month voted unanimously to recommend its approval, the company announced on Friday.

  • 10/13/2017 11:37:21

    BRIEF-Glaxosmithkline says ‍shingles vaccine approved in Canada

    Glaxosmithkline Plc(GSK): * ‍SHINGRIX HAS BEEN APPROVED IN CANADA FOR PREVENTION OF SHINGLES IN PEOPLE AGED 50 YEARS OR OLDER​. * ‍APPROVAL IN CANADA WAS BASED ON PHASE III CLINICAL TRIAL PROGRAMME EVALUATING ITS EFFICACY, SAFETY AND IMMUNOGENICITY IN MORE THAN 37,000 PEOPLE​ Source text for Eikon: Further company coverage:

  • 09/20/2017 00:16:27

    BRIEF-GlaxoSmithkline and Innoviva announces positive impact results for Trelegy in COPD

    * CO, INNOVIVA REPORT POSITIVE HEADLINE RESULTS FROM STUDY SHOWING SINGLE INHALER TRIPLE THERAPY TRELEGY ELLIPTA REDUCED COPD EXACERBATIONS

  • 09/15/2017 00:15:22

    BRIEF-GlaxoSmithKline says Trelegy Ellipta once-daily single inhaler triple therapy receives positive opinion from CHMP in Europe

    * TRELEGY ELLIPTA ONCE-DAILY SINGLE INHALER TRIPLE THERAPY RECEIVES POSITIVE OPINION FROM THE CHMP IN EUROPE FOR APPROPRIATE PATIENTS WITH COPD

  • More trends:

    Global Brass and Copper HoldingsBRSS | Global Cash Access HoldingsGCA | Global High Income Dollar FundGHI | Global Net LeaseGNL | Global Partners LPGLP | Global Payments Inc.GPN | Global Power Equipment Group IncGLPW | Global Ship LeaseGSL | Global Ship LeaseGSL^B | Globant S.A.GLOB |